
New Biotech, Avidicure, Launched to Develop Multifunctional Antibody Modality for Cancer
Netherlands-based Avidicure is a new biotechnology company that has been launched from a $50 million seed financing round. Announcing the launch on April 24, 2025, the company said it aims to develop a new multifunctional antibody modality that will have …